In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The...
In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The...
2024年7月，Rapid Micro Biosystems进行了一项企业-wide审查，以实现运营效率，公司将减少其当前工作人员，关闭已开放和计划职位，并在公司整个业务上减少其他非人员开销。
In July 2024, Rapid Micro Biosystems Completed An Enterprise-wide Review To Realize Operational Efficiencies, The Company Will Reduce Its Current Workforce, Close Open And Planned Positions, And Reduce Other Non-headcount-related Expenses Across The Business
2024年7月，快速微生物生产系统公司进行了全企业审查以实现运营效率，公司将在业务各个领域减少现有员工，关闭已开放和计划职位，以及裁减其他与人员数无关的费用。
These actions are expected to result in approximately $7 million in annual cash savings and enable the Company to achieve positive cash flow by the end of 2027 without additional financing.
这些行动预计将产生约700万美元的年度现金储蓄，并使公司在2027年底之前实现正现金流，无需额外融资。
The Company does not expect these actions to impact its 2024 revenue or gross margin outlook and plans to continue to invest in key initiatives that are expected to drive future revenue growth and gross margin improvement, including product development and cost reduction programs.
公司预计这些行动不会影响其2024年营业收入或毛利率预期，并计划继续投资于预计推动未来营收增长和毛利率改善的关键举措，包括产品开发和成本削减计划。
The Company expects to record a related charge of approximately $0.7 million in the third quarter of 2024.
公司预计将在2024年第三季度录得相关费用约70万美元。
资讯热榜
更新时间